Our lead novel cancer target: BGB001

BGB001 is a monoclonal antibody therapeutic against a novel receptor Tyrosin Kinase. This target is indicated in many metastatic cancers particularly ones with an EMT activity.

Learn more about the EMT process

Pipeline

Cancer is the Number One Killer World-wide

More than 1 in 3 people will die of cancer. Indeed, today the standard of care available for many cancer patients treats the primary tumour very effectively.

Unfortunately, many cancers metastasise and secondary tumours seed and develop in other organs.

Worse still, these secondary tumours tend to be resistant to the drugs that are currently available and ultimately patients die from the effects of these metastatic tumours.

BerGenBio's Oncology Vision

BerGenBio's Oncology R&D program is focused on the development of a first-in-class Epithelial-Mesenchymal Transition (EMT) inhibitor drugs that block the mechanisms by which tumour cells metastasise and become drug resistant.